Zoetis
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
73% more first-time investments, than exits
New positions opened: 242 | Existing positions closed: 140
4% more funds holding
Funds holding: 1,754 [Q3] → 1,823 (+69) [Q4]
0.45% less ownership
Funds ownership: 92.83% [Q3] → 92.38% (-0.45%) [Q4]
8% less repeat investments, than reductions
Existing positions increased: 654 | Existing positions reduced: 714
14% less call options, than puts
Call options by funds: $221M | Put options by funds: $258M
16% less capital invested
Capital invested by funds: $80.9B [Q3] → $67.9B (-$13B) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 26 [Q3] → 13 (-13) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$180
9%
upside
Avg. target
$217
31%
upside
High target
$244
48%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler David Westenberg 49% 1-year accuracy 21 / 43 met price target | 24%upside $205 | Overweight Maintained | 27 Feb 2025 |
Barclays Balaji Prasad 32% 1-year accuracy 14 / 44 met price target | 48%upside $244 | Overweight Maintained | 14 Feb 2025 |
Morgan Stanley Erin Wright 60% 1-year accuracy 15 / 25 met price target | 44%upside $238 | Overweight Maintained | 14 Feb 2025 |
Stifel Jonathan Block 21% 1-year accuracy 4 / 19 met price target | 9%upside $180 | Buy Maintained | 7 Jan 2025 |
Financial journalist opinion
Based on 10 articles about ZTS published over the past 30 days
Negative
The Motley Fool
10 hours ago
Zoetis' Stock Is About as Cheap as It's Ever Been. 1 Thing to Know Before You Buy.
Shares in animal pharmaceutical company Zoetis (ZTS 0.14%) have been under a cloud since the release of the company's fourth-quarter earnings report in mid-February. The Q4 numbers were fine, but the company's revenue guidance fell short of expectations.

Neutral
Business Wire
11 hours ago
Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations.

Positive
Seeking Alpha
2 days ago
Zoetis: Lots Of Growth Opportunities For This High-Quality Compounder
Zoetis is currently cheap from a historical perspective, presenting a potential buying opportunity. The company operates in a growing animal healthcare market, benefiting from trends like pet humanization and medicalization, ensuring long-term growth. ZTS has a strong track record of market outperformance, impressive margins, and a high ROIC, making it a high-quality company.

Neutral
Zacks Investment Research
6 days ago
Zoetis (ZTS) Stock Declines While Market Improves: Some Information for Investors
Zoetis (ZTS) closed the most recent trading day at $163.03, moving -0.08% from the previous trading session.

Neutral
Zacks Investment Research
2 weeks ago
Why Zoetis (ZTS) Dipped More Than Broader Market Today
The latest trading day saw Zoetis (ZTS) settling at $160.06, representing a -1% change from its previous close.

Positive
Seeking Alpha
2 weeks ago
Zoetis: Focusing On The High Margin Segments
The recent divestiture of the MFA segment improves margins and returns on capital. Zoetis is focusing on more profitable segments like genetics and companion animals. The recently updated Librela label includes adverse effects and urges practitioners to discuss potential adverse reactions with clients.

Neutral
Seeking Alpha
2 weeks ago
Zoetis Inc. (ZTS) CFO Wetteny Joseph Hosts Barclays 27th Annual Global Healthcare (Transcript)
Zoetis Inc. (NYSE:ZTS ) Barclays 27th Annual Global Healthcare March 11, 2025 10:30 AM ET Company Participants Wetteny Joseph - Chief Financial Officer Conference Call Participants Balaji Prasad - Barclays Balaji Prasad Good morning, everyone. Thanks for joining us at the Barclays Healthcare Conference.

Neutral
Zacks Investment Research
2 weeks ago
Zoetis (ZTS) Laps the Stock Market: Here's Why
Zoetis (ZTS) reachead $170.37 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.

Positive
Seeking Alpha
3 weeks ago
My Top 15 High-Growth Dividend Stocks For March 2025
The SPDR S&P 500 ETF Trust stumbled in February but managed to maintain a positive return in 2025. The Top 15 dividend growth stocks for March 2025 offer an average dividend yield of 1.13% and appear to be about 25% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 10.63% compound annual growth rate.

Neutral
Seeking Alpha
3 weeks ago
Zoetis Inc. (ZTS) BofA Securities 2025 Animal Health Summit (Transcript)
Zoetis Inc. (NYSE:ZTS ) BofA Securities 2025 Animal Health Summit February 27, 2025 1:20 PM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Michael Ryskin - Bank of America Operator Ladies and gentlemen, the program is about to begin. At this time, it is my pleasure to turn the program over to your host, Michael Ryskin.

Charts implemented using Lightweight Charts™